Home › Employers › ROME Therapeutics, Inc.
ROME Therapeutics, Inc.: H-1B salaries and sponsorship
ROME Therapeutics, Inc. filed 3 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $145,000.
Does ROME Therapeutics, Inc. sponsor H-1B visas?
ROME Therapeutics, Inc. filed 3 labor condition applications in fiscal years 2023–2026, the latest submitted on Sep 18, 2024. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Data Scientist (Deep Learning for Computational Biology) | 2 | $145,000 |
| Senior Research Associate | 1 | $85,000 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2024 | 3 | $145,000 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Data Scientist (Deep Learning for Computational Biology) | $145,000–$155,000 Level IV | Lafayette, CO | Sep 18, 2024 | Oct 1, 2024 | Certified |
| Data Scientist (Deep Learning for Computational Biology) | $145,000–$155,000 Level IV | Boston, MA | Apr 4, 2024 | Oct 1, 2024 | Certified |
| Senior Research Associate | $85,000–$105,000 Level II | Brighton MA, MA | Nov 17, 2021 | Dec 1, 2021 | Certified, then withdrawn |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).